Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis

• Published in: Rheumatology (Oxford, England) Vol. 56; no. 3; p. kew442
• Main Authors: Tarp, Simon, Eric Furst, Daniel, Boers, Maarten, Luta, George, Bliddal, Henning, Tarp, Ulrik, Heller Asmussen, Karsten, Brock, Birgitte, Dossing, Anna, Schjødt Jørgensen, Tanja, Thirstrup, Steffen, Christensen, Robin
• Format: Journal Article
• Language: English
• Published: England 01.03.2017
• Subjects: Abatacept - adverse effects; Adalimumab - adverse effects; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - adverse effects; Antirheumatic Agents - adverse effects; Arthritis, Rheumatoid - drug therapy; Biological Products - adverse effects; Certolizumab Pegol - adverse effects; Etanercept - adverse effects; Humans; Piperidines - adverse effects; Poisson Distribution; Pyrimidines - adverse effects; Pyrroles - adverse effects; Regression Analysis; Risk; Rituximab - adverse effects; serious adverse events; meta-analysis; mortality; indirect comparison; network meta-analysis; systematic review; rheumatoid arthritis; targeted synthetic disease-modifying antirheumatic drugs; biological agents

To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts...